Kuros Biosciences AG Company Description

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing.

The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG

Country	Switzerland
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	122
CEO	Christopher Fair

Contact Details

Address: Wagistrasse 25 Schlieren, 8952 Switzerland
Phone	41 44 733 4747
Website	kurosbio.com

Stock Details

Ticker Symbol	0RHR
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH0325814116
SIC Code	2836

Key Executives

Name	Position
Prof. Joost D. de Bruijn B.S., Ph.D., B.Sc. Ph.D.	Chief Executive Officer and Director
Michael Grau M.B.A., MBA	Chief Financial Officer
Dr. Alistair Irvine	Chief Business Officer
Dr. Philippe Saudan Ph.D.	Chief Development Officer
Frank-Jan van der Velden MBA	Head of Business Affairs and Finance of Kuros Biosciences B.V.
Dr. Pascal Longlade	Chief Medical Officer
Dr. Oliver P. Kronenberg	Senior Legal Counsel
Dr. Charlie Campion	Senior Vice President of Marketing and International Sales
John Griffin	Head of Commercial Operations
Florence Barrere de Groot	Head of Development